Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Alignment Healthcare Chief Executive John E. Kao sold 250,000 shares on April 7, 2026, realizing roughly $5.25 million across two trades conducted under a pre-arranged Rule 10b5-1 plan. The sales occurred as ALHC shares climbed about 19.5% over the prior week, while the company reported robust fourth-quarter metrics and disclosed a General Atlantic…
Norman Prestage, a director at Lamb Weston Holdings, purchased 2,500 shares on April 7, 2026 for $41.40 each, a $103,500 transaction recorded on a Form 4 filing. The purchase increases his direct holdings to 9,481.7 shares. The move comes after a 34% fall in the stock over six months and amid updated fiscal 2026 guidance lifting midpoint revenue an…
Verisign Executive Vice President, General Counsel, and Secretary Thomas C. Indelicarto sold 498 shares of Verisign stock on April 7, 2026, for $136,452. The transaction coincides with a recent 8% one-week stock rise and third-party analysis that places the company on an overvalued list. The company’s reported fourth-quarter 2025 results showed a r…
Photronics INC director Lee Kang Jyh sold 5,000 shares on April 6, 2026, after exercising 5,000 stock options. The transactions occurred as the company reported fiscal Q1 2026 results that beat expectations and announced the installation of a new mask writer in Korea, while the stock trades notably higher year-over-year.
Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics (PTCT), sold 2,265 shares on April 6, 2026, in transactions totaling $157,293 and exercised options to acquire the same number of shares at $39.42. Following the activity, Boulding holds 105,212 shares. The trades were carried out under a pre-arranged plan a…
MediaAlpha, Inc. (NASDAQ: MAX) Chief Executive Steven Yi sold 12,000 shares of Class A common stock across three trades from April 6 to April 8, 2026, totaling about $114,335. The sales were carried out under a Rule 10b5-1 trading plan to cover taxes from RSU vesting. The company recently reported fourth-quarter 2025 revenue of $291 million, below …
Entegris Inc. (NASDAQ: ENTG) General Counsel Joseph Colella sold 1,592 shares on April 7, 2026, in a transaction worth $183,987 under a Rule 10b5-1 plan. The stock has since risen to $129.60, representing a 41% year-to-date gain and an 89% return over the prior 12 months. Entegris also reported Q4 2025 results that topped expectations, prompting BM…
Mat Ishbia and SFS Holding Corp., a greater-than-10% stakeholder in UWM Holdings Corp., sold a combined 2,001,148 shares of Class A common stock on April 7 and April 8, 2026, in two transactions totaling roughly $7.48 million. The trades were executed under a 10b5-1 trading plan. The disclosures come as UWM reports stronger-than-expected fourth-qua…
Director Laurie Harris sold 5,531 shares of Hagerty, Inc. Class A common stock on April 7, 2026, through an automatic trading arrangement established in November 2025. The sale, which generated roughly $60,896, followed restricted stock unit vesting and leaves Harris with 36,689 shares. Hagerty recently reported Q4 2025 results that exceeded analys…
EverCommerce Inc. President Matthew David Feierstein sold 15,000 shares on April 6 and 7, 2026, for proceeds of $175,970 under a Rule 10b5-1 plan. The company recently reported fourth-quarter 2025 results that included an EPS of $0.03 versus an expected $0.05 and revenue of $151.2 million versus a $150.36 million forecast. At a market price of $11.…
The Hershey Trust Co., acting as trustee for the Milton Hershey School, disclosed the sale of common shares in The Hershey Co. on April 6, 7 and 8, 2026. The filings show sales totaling roughly $6.2 million at prices between $205.45 and $208.5732. Following the transactions the trust's direct and indirect holdings were reported, and recent analyst …
Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 3,970 shares on April 6, 2026, for about $71,508, after exercising options for the same number of shares at $12.65 each. The transactions were carried out under a Rule 10b5-1 plan. Meanwhile, several analysts reiterated or initiated Buy/Outperform ratings and adjusted price targets as the c…
Jeffrey W. Priest, President and CEO of General American Investors Co Inc (GAM), purchased 5,000 shares of the company's 5.95% preferred stock on April 8, 2026, paying $24.685 per share for a total of $123,425. The transaction was recorded as a purchase of Non-Derivative Securities and raises his direct preferred-stock holdings to 40,691 shares. Pr…
Luxor Capital LLC, controlled by Anthony Brian Goodman, sold 1,254 shares of Meridian Holdings Inc./NV (NASDAQ:MRDN) across two trades on March 31 and April 7, 2026, for a combined $8,739. The disposals left Luxor with 808,673 shares. Meridian has recently reported Q4 2025 results that missed expectations, reduced debt materially through the third …
Elizabeth A. Porter, a sector president at Leidos Holdings, filed a Form 4 reporting the sale of 2,000 shares on April 7, 2026. The disposals, executed under a pre-arranged trading plan, generated roughly $317,555 in gross proceeds. The transactions come as Leidos' shares trade near $160.64, following a roughly 19% decline over six months, and amid…
Boston Omaha Corporation, a roughly 10% holder of Sky Harbour Group Corp (SKYH), sold 331,500 Class A shares on April 6, 2026 for $9.05 per share, netting $3,000,075. The transaction, reported on a Form 4 signed April 8, 2026, leaves Boston Omaha with direct and subsidiary holdings plus warrants. Sky Harbour’s share price has since risen to $10.21,…
Olivier Blachier, Entegris' SVP and Chief Strategy Officer, sold 275 shares on April 7, 2026, under a Rule 10b5-1 plan. The transaction totaled $31,781. Since the sale the stock has risen to $129.60, an 89% gain over the last year. Entegris reported Q4 2025 results that beat expectations, prompting price-target increases from BMO Capital and KeyBan…
Control Empresarial de Capitales S.A. de C.V., a roughly 10% shareholder of PBF Energy Inc. (NYSE: PBF), sold 200,000 Class A common shares on April 6-7, 2026, netting $9.3 million at prices between $46.1808 and $47.5276. The transactions reduce the entity's direct stake to 19,253,698 shares. The move occurs amid mixed Q4 2025 results for PBF - an …
Robinhood Markets Chief Technology Officer Jeffrey Tsvi Pinner sold 5,835 shares of Class A common stock on April 6, 2026, in two trades totaling about $407,574. The disposals were carried out under a pre-established Rule 10b5-1 trading plan. The share movements come against a backdrop of pronounced price swings, several analyst price-target reduct…
Insmed Inc's Chair and CEO, William Lewis, sold 10,700 shares on April 6, 2026, generating $1,746,335 in proceeds and separately exercised options to acquire 10,699 shares. The equity moves coincide with the company's halt of its hidradenitis suppurativa program following a failed Phase 2b CEDAR study and subsequent analyst price-target adjustments…
Robinhood Markets CEO Vladimir Tenev sold 375,000 Class A shares on April 6, 2026, in transactions totaling $26.19 million under a Rule 10b5-1 plan, and converted an equal number of Class B shares into Class A on the same day. The share sales occurred at prices modestly below the stock's prevailing market level. Several firms have since lowered pri…
Michael S. Harper, zSpace Inc.'s Chief Product, Engineering and Marketing Officer, sold 7,586 shares on April 7, 2026 to satisfy tax obligations tied to vested restricted stock units. The disposal came amid a sharp year-over-year revenue decline, ongoing cash burn, and a sharply reduced analyst price target, underscoring the financial strains confr…
zSpace Chief Executive Paul Kellenberger sold 20,758 shares on April 7, 2026, in a Form 4 filing, raising $1,536 at a weighted average price of $0.074 to cover taxes from a prior RSU vesting. The augmented reality developer, with a $3.98 million market cap, has seen its stock fall nearly 99% over the past year and reported a 43% year-over-year reve…
Eugene S. Stark, Vice President Administration/CCO/PFO at General American Investors Co Inc (NYSE: GAM), purchased additional 5.95% Preferred Stock on April 8, 2026, spending $152,932 across transactions at $24.85 to $24.92 per share. The move increases his direct and indirect holdings across preferred and common shares, while GAM’s common stock ha…
Castle Biosciences President and CEO Derek J Maetzold sold 9,748 shares on April 6, 2026, for $246,195 and simultaneously exercised options to acquire 6,214 shares. The company recently reported better-than-expected fourth-quarter 2025 financial results and disclosed clinical data on its DecisionDx-Melanoma test.
